Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | SCN1A | P35498 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27859193 | 0.79 | MAPK1 (0.63) | MAPTSMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL8603615 | 0.79 | MAPK1 (0.63) | MAPTSMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL6901262 | 0.78 | PTGES (0.52) | MAPTSMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL4723804 | 0.78 | ALDH1A1 (0.69) | MAPTSMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL7057377 | 0.76 | DYRK3 (0.54) | MAPTSMN1; SMN2NPC1RAB9AHSD17B10 | |
| SCHEMBL6895297 | 0.75 | PLK4 (0.52) | MAPTSMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL6899514 | 0.73 | L3MBTL1 (0.54) | L3MBTL1LMNA | |
| SCHEMBL18405944 | 0.73 | ALDH1A1 (0.55) | MAPTSMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL4724739 | 0.72 | ALDH1A1 (0.59) | MAPTSMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL7072639 | 0.72 | MAPT (0.56) | MAPTKCNH2ABL1MAPK10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1635890-A | Neuroprotective 2-pyridinamine compositions and related methods | ORTHO MCNEIL PHARM INC (US) | 2005-07-06 | — | — | CN | claimed |
| JP-2004510707-A | — | — | 2004-04-08 | — | — | JP | claimed |
| US-20030225085-A1 | 2-pyridinamine compositions and related methods | GRANT ELFRIDA R (US) | 2003-12-04 | — | — | US | claimed |
| EP-1317266-A2 | NEUROPROTECTIVE 2-PYRIDINAMINE COMPOSITIONS AND RELATED METHODS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-06-11 | — | — | EP | claimed |
| US-20020198219-A1 | 2-pyridinamine compositions and related methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-12-26 | — | — | US | claimed |
| WO-2002011724-A2 | NEUROPROTECTIVE 2-PYRIDINAMINE COMPOSITIONS AND RELATED METHODS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-02-14 | — | — | WO | claimed |
| CN-1635890-A | Neuroprotective 2-pyridinamine compositions and related methods | ORTHO MCNEIL PHARM INC (US) | 2005-07-06 | — | — | CN | disclosed |
| US-20030225085-A1 | 2-pyridinamine compositions and related methods | GRANT ELFRIDA R (US) | 2003-12-04 | — | — | US | disclosed |
| EP-1317266-A2 | NEUROPROTECTIVE 2-PYRIDINAMINE COMPOSITIONS AND RELATED METHODS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-06-11 | — | — | EP | disclosed |
| US-20020198219-A1 | 2-pyridinamine compositions and related methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-12-26 | — | — | US | disclosed |
| WO-2002011724-A2 | NEUROPROTECTIVE 2-PYRIDINAMINE COMPOSITIONS AND RELATED METHODS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225085-A1 | 2-pyridinamine compositions and related methods | AIFM1, CASP5, CASP2 | MAPT 403/4885SMN1; SMN2 37/4885NPC1 1405/4885 |
| US-20020198219-A1 | 2-pyridinamine compositions and related methods | AIFM1, CASP5, CASP2 | MAPT 403/4885SMN1; SMN2 37/4885NPC1 1405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.